Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Precigen (PGEN)
NASDAQ:PGEN
PGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $2.17
Previous CloseN/A
Volume729.99K
Average Volume (3M)1.95M
Market Cap
$576.95M
Enterprise Value$238.41M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Feb 26, 2025EPS Estimate
-0.06Last Dividend Ex-Date
Jan 19, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding292,869,100
10 Day Avg. Volume2,647,288
30 Day Avg. Volume1,953,716
Standard Deviation0.27
R-Squared0.10
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)217.38
Price to Cash Flow (P/CF)-6.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.25K
Enterprise Value/Ebitda-1.75
Forecast
1Y Price Target
$5.50Price Target Upside179.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Precigen News
PremiumCompany Announcements
Precigen Secures $79M Financing for 2025 Launch
PremiumCompany Announcements
Precigen Reports Q3 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Commercial PotentialThe submission of the BLA for PRGN-2012 is seen as a significant step, with the potential to establish it as the standard of care for treating recurrent respiratory papillomatosis.
Financial StabilityThe company's fundraising efforts, raising $87.5 million in gross proceeds, extend cash runway well into 2026.
Market OpportunityPRGN-2012 is expected to get to market first, ahead of its competitor, due to high likelihood of accelerated approval and a superior complete response rate.
Bears Say
Competitive LandscapeThe anticipated robust launch of PRGN-2012 faces the challenge of establishing itself in a multi-billion dollar market where no FDA-approved drug currently exists.
Market DynamicsDespite strong Phase 2 data, the commercial success of PRGN-2012 will depend on overcoming the high surgery burden currently faced by patients.
Regulatory HurdlesThe transition to a commercial stage is pending a positive FDA decision on the BLA for PRGN-2012, which introduces regulatory uncertainty.
---
Ownership Overview
42.78% Insiders
12.73% Mutual Funds
12.65% Other Institutional Investors
26.21% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PGEN FAQ
What was Precigen’s price range in the past 12 months?
Precigen lowest stock price was $0.65 and its highest was $2.17 in the past 12 months.
What is Precigen’s market cap?
Precigen’s market cap is $576.95M.
When is Precigen’s upcoming earnings report date?
Precigen’s upcoming earnings report date is Feb 26, 2025 which is in 4 days.
How were Precigen’s earnings last quarter?
Precigen released its earnings results on Nov 14, 2024. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.086 by -$0.004.
Is Precigen overvalued?
According to Wall Street analysts Precigen’s price is currently Undervalued.
Does Precigen pay dividends?
Precigen pays a Notavailable dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Precigen dividends here
What is Precigen’s EPS estimate?
Precigen’s EPS estimate is -0.06.
How many shares outstanding does Precigen have?
Precigen has 292,869,100 shares outstanding.
What happened to Precigen’s price movement after its last earnings report?
Precigen reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.086. Following the earnings report the stock price went down -6.818%.
Which hedge fund is a major shareholder of Precigen?
Currently, no hedge funds are holding shares in PGEN
---
Precigen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.50 (179.19% Upside)
$5.50 (179.19% Upside)
Blogger Sentiment
Bullish
PGEN Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.73%
12-Months-Change
Fundamentals
Return on Equity
-137.46%
Trailing 12-Months
Asset Growth
-56.22%
Trailing 12-Months
Company Description
Precigen
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
---
PGEN Stock 12 Month Forecast
Average Price Target
$5.50
▲(179.19% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering PGEN
1 Year
1 Year Success Rate
11/26 ratings generated profit
1 Year Average Return
-3.40%
reiterated a buy rating last month
Copying Jason Butler's trades and holding each position for 1 Year would result in 42.31% of your transactions generating a profit, with an average return of -3.40% per trade.
---